OXE103
Persistent Concussion Symptoms (Post-Concussion Syndrome)
Phase 2b (Planned)Active
Key Facts
Indication
Persistent Concussion Symptoms (Post-Concussion Syndrome)
Phase
Phase 2b (Planned)
Status
Active
Company
About Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a private, pre-revenue biotech targeting a significant unmet need: an FDA-approved therapy for persistent concussion symptoms (post-concussion syndrome). The company's lead small molecule drug, OXE103, showed an 85% responder rate in a Phase 2a pilot study, positioning it for a planned Phase 2b trial in 2026. Oxeia is currently raising capital via an equity crowdfunding campaign on StartEngine to fund this next development stage, operating in a large market with no approved pharmacological treatments.
View full company profile